Skip to content

Ketoanalogues in chronic kidney disease

Effects of Keto-analogues on patients with chronic kidney disease

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230318057755N1
Enrollment
32
Registered
2024-12-14
Start date
2024-07-07
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease. Chronic kidney disease (CKD)

Interventions

Intervention 1: The intervention group: included 16 people who received catalog pills and a very low protein diet for three months. The very low protein diet has been adjusted by receiving a food plan

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed with diabetic nephropathy Patients diagnosed with chronic kidney disease

Exclusion criteria

Exclusion criteria: Patients undergoing hemodialysis Patients diagnosed with hypercalcemia

Design outcomes

Primary

MeasureTime frame
Decrease proteinuria. Timepoint: At the beginning of the study and 3 months later. Method of measurement: Urine analysis.;Postponement of hemodialysis. Timepoint: Three months after the start of the study. Method of measurement: Based on kidney function(eGFR), BUN and creatinine levels.;Improving the state of metabolic regulation of the body. Timepoint: At the beginning of the study and 3 months later. Method of measurement: Based on the patient's blood tests such as calcium, phosphorus, potassium, etc.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Torabi Jahromi

Shiraz University of Medical Sciences

torabijm@sums.ac.ir+98 917 791 2256

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026